Adocia (Adocia) Debt-to-Asset : 0.52 (As of Dec. 2023)

View and export this data going back to 2013. Start your Free Trial

What is Adocia Debt-to-Asset?

Adocia's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $1.98 Mil. Adocia's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $12.29 Mil. Adocia's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2023 was $27.22 Mil. Adocia's debt to asset for the quarter that ended in Dec. 2023 was 0.52.

Adocia Debt-to-Asset Historical Data

The historical data trend for Adocia's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adocia Debt-to-Asset Chart

Adocia Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Asset

Get a 7-Day Free Trial

0.34

0.62

1.15

1.09

0.52

Adocia Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-Asset	Get a 7-Day Free Trial															1.15	0.72	1.09	1.36	0.52

Competitive Comparison of Adocia's Debt-to-Asset

For the Biotechnology subindustry, Adocia's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Adocia's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Adocia's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Adocia's Debt-to-Asset falls into.

Adocia Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Adocia's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(1.981	+	12.292)	/	27.215
	=	0.52

Adocia's Debt-to-Asset for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(1.981	+	12.292)	/	27.215
	=	0.52

Adocia (OTCPK:ADOIF) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Adocia Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Adocia's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Adocia (Adocia) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adocia (OTCPK:ADOIF) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

ADOC:France A89:Germany

Address

115 Avenue Lacassagne, Lyon, FRA, 69003

Website

https://www.adocia.com

Adocia is a clinical-stage biotechnology company. It specializes in the development of formulations of already approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. The firm has developed Biochaperone, a proprietary technology platform to enhance the effectiveness of therapeutic proteins. The company's clinical pipeline includes Biochaperone Lispro, Biochaparone Combo, Biochaparone Glucagon, and others. Its pre-clinical pipeline includes BioChaperone LisPram, BioChaperone Glargine GLP-1, and BioChaperone Glucagon GLP1. Its patent portfolio mainly consists of chronic wound healing, insulin therapy, and monoclonal antibodies.